FDA: Page 18
-
Medtronic receives CE mark for CGM sensor, boosting challenge to Abbott and Dexcom
Medtronic has made the sensor smaller and eliminated the need for fingersticks to calibrate the device, bringing a challenger to market leaders Abbott and Dexcom.
By Nick Paul Taylor • Sept. 25, 2023 -
FDA shares draft medical device harmonization plan to meet MDUFA V goal
The FDA outlined deadlines for actions it will take, including creating a mechanism for working with regulatory partners.
By Nick Paul Taylor • Sept. 25, 2023 -
Explore the Trendlineâž”
Sitthiphong via Getty ImagesTrendlineMedical device industry continues to turn to AI
While the industry continues to embrace artificial intelligence, there are still questions about how the new technologies need to be regulated and if they are effective.
By MedTech Dive staff -
"Government Accountability Office Building" by kafka4prez is licensed under CC BY-SA 2.0
Limited resources constrain federal oversight of medical device ads, GAO finds
U.S. agencies took 322 enforcement actions related to medtech advertising between 2018 and 2022.
By Nick Paul Taylor • Sept. 21, 2023 -
EU antitrust officials make surprise inspections at cardiovascular device company
The unnamed company may have violated EU rules against abusing a dominant market position, the European Commission said.
By Susan Kelly • Sept. 20, 2023 -
CMS leader defends breakthrough device reimbursement proposal at House hearing
Dora Hughes made the case for restricting the Transitional Coverage for Emerging Technologies pathway to five reviews a year.
By Nick Paul Taylor • Sept. 20, 2023 -
FDA makes device conformity testing scheme permanent to streamline assessments
The FDA has delivered on a MDUFA V commitment by turning ASCA into a permanent, voluntary accreditation program.
By Nick Paul Taylor • Sept. 20, 2023 -
FDA releases draft guidance for studying weight loss devices
The documents arrive amid questions about whether new medicines will cut demand for weight loss procedures.
By Nick Paul Taylor • Sept. 19, 2023 -
MedTech Europe says MDR, IVDR framework needs ‘structural reform’
Patients may face delayed access to treatments unless changes are made to the new regulatory system, 35 European trade groups warned in an open letter.
By Susan Kelly • Sept. 18, 2023 -
FDA finalizes breakthrough device changes to target health inequities
The proposals received positive feedback from groups including AdvaMed, leading the FDA to finalize the changes with only minor revisions.
By Nick Paul Taylor • Sept. 18, 2023 -
Beacon Biosignals receives FDA clearance for sleep tracking headband
The company’s at-home device, the Dreem 3S, has six EEG electrodes to capture brain activity.
By Nick Paul Taylor • Sept. 18, 2023 -
Abbott’s neurostimulator recall, with 73 injuries reported, deemed Class I by FDA
The company contacted customers in July after receiving complaints from patients who were unable to exit the devices’ MRI mode.
By Nick Paul Taylor • Sept. 14, 2023 -
FDA finalizes biocompatibility guidance for devices that touch the skin
The agency chose not to make some major requested revisions, such as including metals in the scope of the guidance.
By Nick Paul Taylor • Sept. 14, 2023 -
FDA finalizes combination product guidance 7 years after sharing draft
AdvaMed called overlapping human factor requirements of the draft guidance “overly burdensome.”
By Nick Paul Taylor • Sept. 13, 2023 -
TB deaths prompt FDA warning on reducing transmission risk
The agency outlined risk mitigation strategies for cell and tissue products after two recipients of bone matrix products died.
By Nick Paul Taylor • Sept. 13, 2023 -
CMS digs deeper into impact of proposed breakthrough device pathway in JAMA paper
The article discusses what the TCET pathway will mean for products at different stages of the life cycle.
By Nick Paul Taylor • Sept. 12, 2023 -
FDA proposes 3 guidances to improve 510(k) clearance process
The agency has made recommendations for selecting predicate devices, using clinical data and conducting performance testing for implants.
By Nick Paul Taylor • Sept. 7, 2023 -
Boston Scientific gets FDA nod for latest device in fast-growing Watchman franchise
Analysts at RBC Capital Markets called the Watchman FLX Pro approval an “incremental positive” for Boston Scientific.
By Nick Paul Taylor • Sept. 7, 2023 -
23andMe wins FDA clearance to test for expanded set of BRCA cancer risk variants
The new version of the test can report more cancer-related gene mutations, and 23andMe can add variants in the future under an agreement with the FDA.
By Nick Paul Taylor • Sept. 5, 2023 -
UK regulators name 3 approved bodies to ease device certification bottleneck
A MHRA leader hailed the action as “almost doubling capacity for medical device assessment in the U.K.”
By Nick Paul Taylor • Aug. 31, 2023 -
Hamilton Medical’s urgent ventilator notice deemed Class I recall by FDA
The company contacted customers in June after learning that long-term use of the devices could cause them to stop providing active ventilation.
By Nick Paul Taylor • Aug. 31, 2023 -
Trade groups urge CMS to expand, quickly finalize breakthrough device pathway
The groups want changes that include expanding the program to cover breakthrough diagnostics and previously authorized products.
By Nick Paul Taylor • Aug. 30, 2023 -
Withings wins FDA clearance for scale with AFib detection
The device records the electrical signal from the heart, assesses the number of calories the body burns at rest and tracks other health variables.
By Nick Paul Taylor • Aug. 30, 2023 -
Photo by Anna Tarazevich from Pexels
Hopes dim for Medtronic hypertension treatment after FDA panel rebuff
Analysts foresee hurdles to reimbursement even if the device wins the agency’s nod, and some don’t expect approval at all.
By Susan Kelly • Aug. 29, 2023 -
US signs consent decree requiring EPA to finalize ethylene oxide rule by March
A medtech trade group called the deadline inadequate for the EPA to complete the “substantial” work that remains.
By Nick Paul Taylor • Aug. 28, 2023 -
Medtronic renal denervation device hits setback at FDA panel
The agency’s outside advisers found the risks of the procedure to lower blood pressure outweighed the benefits in a narrow vote.
By Susan Kelly • Aug. 24, 2023